神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望培訓講義課件_第1頁
神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望培訓講義課件_第2頁
神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望培訓講義課件_第3頁
神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望培訓講義課件_第4頁
神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望培訓講義課件_第5頁
已閱讀5頁,還剩29頁未讀, 繼續(xù)免費閱讀

下載本文檔

版權說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權,請進行舉報或認領

文檔簡介

神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望(優(yōu)選)神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望胎兒神經(jīng)干細胞治療帕金森氏病臨床研究發(fā)展歷程EvansJR,MasonSL,BarkerRA.ProgBrainRes.2012;200:169-98LindvallO,etal,NatMed.2008May;14(5):501-3THSynucleinOverlayTransplantedfetalmesencephalicdopaminergicneurons(11-16years)developedalpha-synuclein-positiveLewybodiesingraftedneuronsSynuclein-HostUbiquintin-HostSynuclein-GraftedNeuronsUbiquintin-GraftedNeuronsGraftednigralneuronswerefoundtohaveLewybody-likeinclusions14yearsaftertransplantationintothestriatumofanindividualwithPDOlanowCW.etalNatMed.2008May;14(5):504-6.TransplanteddopamineneuronsinpeoplewithPDdonotcontainLewybodiesMendez,Isacsonetal,,NATUREMEDICINEVOLUME14(5):507-509,2008FreedCR,JNuclMed.2010Jan;51(1):7-15-LongtermStudy-33oftheoriginaltrialparticipantswhowerefollowedfor2yearsaftertransplantationand15ofthesesubjectswhowerefollowedfor2additionalyears.-Theseresultssuggestthatclinicalbenefitandgraftviabilityaresustainedupto4yaftertransplantation.

FreedCR,Neurotherapeutics(2011)8:549–561人體胚胎干細胞分化的多巴胺神經(jīng)元移植

改善小鼠,大鼠和猴子帕金森氏病的運動障礙22/29DECEMBER2011|VOL480|NATURE|547,LorenzStuder,etal

MemorialSloan-KetteringCancerCenterImprovedCellTherapyProtocolforParkinson’sDiseaseBasedonDifferentiationEfficiencyandSafetyofhESC-,HipscandNon-HumanPrimateiPSC-DerivedDANeuronsIsacsonetal,,StemCells.2013;31(8):1548-62.DopaminereleasefromtransplantedneuralstemcellsinParkinsonianratstriatuminvivo.Twelvepatientsweretreatedwitheitherunilateralorbilateralinjections.6OHDAinducedRatPDModel分化的胎腦神經(jīng)干細胞移植治療PDIncreasinghostneurogenesis“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.TodeterminewhetherlocalmechanismsmediateBMSCneuroprotectiveactionsetalNatMed.(優(yōu)選)神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望胎兒神經(jīng)干細胞治療帕金森氏病臨床研究發(fā)展歷程Releaseofimmuno-regulatoryfactorssuchasIL-2,6,8,10toplayimmuno-modulationandattenuationoftheinflammatoryprocess,suchasMSC.2012;200:169-98ImprovedCellTherapyProtocolforParkinson’sDiseaseBasedonDifferentiationEfficiencyandSafetyofhESC-,HipscandNon-HumanPrimateiPSC-DerivedDANeuronsIntraspinalstemcelltransplantationinALS:aphaseItrial,2014Anotherrequiredreoperationforwounddehiscenceandinfection.usingESCsandiPSCsiPSCellsWereGeneratedfromPDpatientsandNormalControlsUbiquintin-GraftedNeuronsIncreasinghostneurogenesisgraftedallogeneicBMSCstositesofsevere,compressive

spinalcordinjury

(SCI)inSpragueDawleyrats.DopaminereleasefromtransplantedneuralstemcellsinParkinsonianratstriatuminvivo.

Zhouz,etal,ProcNatlAcadSciUSA.2014Nov4;111(44):15804-9iPSCDerivedDopamineNeuronsfunctionafterTransplantationinaNonHumanPrimateModelofParkinson’sDiseaseCellStemCell.2015Mar5;16(3):269-74.

OleIsacsonetal,HarvardStemCellInstituteStemcellbasedClinicalTrialsfor(ALS)Nuralstem,Inc.thefirstPhaseIclinicaltrialforastemcell-basedtreatmentofALS.Initiatedin2010andcompletedin2013,involvedthetransplan-tationofhumanspinalcord-derivedNSCsintothespinalcordof15latetomid-stageALSpatients“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.SummaryonMolecularMechanismofStemCellTransplantationforNeurologicalDiseasestoincreasethefunctionsoftheendogenousneuralstemcellsThisencouragingfindingsupportsconsiderationofthisdeliveryapproachforneurodegenerative,oncologic,andtraumaticspinalcordafflictions.暴露和部分橫切脊髓外科手術。University,Atlanta,Georgia;DepartmentofNeurology,EmoryUniversity,Atlanta,Georgia;DepartmentofNeurology,UniversityofMichigan,AnnArbor,MichiganGlass,Feldman,E.RTPCRtoDetecttheMicroRNAExpressioninRatSCIModelPatientsarefollowedclinicallyandradiologicallytoassesspotentialtoxicityoftheprocedure.Cells

wereadministered48hoursaftertheoriginal

injury.SCgraftsshouldexhibitregulatedreleaseofdopamineinlinewiththatofendogenousdopaminergicneurons.-LongtermStudy神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望Isacsonetal,,StemCells.神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望RealTimeRTPCRtoDetecttheMicroRNAExpressioninSCIiPSCellsWereGeneratedfromPDpatientsandNormalControlsGlass,Feldman,E.Thus,allogeneicgraftsofBMSCsdonotappeartoactthroughlocalmechanisms,andfuture

clinicaltrials

thatacutelydeliverBMSCstoactualsitesof

injury

withindaysareunlikelytobebeneficial.Ubiquintin-GraftedNeurons“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.Thisencouragingfindingsupportsconsiderationofthisdeliveryapproachforneurodegenerative,oncologic,andtraumaticspinalcordafflictions.IntraspinalstemcelltransplantationinALS:aphaseItrial,2014Glass,Feldman,E.L.,2012.Lumbarintraspinalinjectionofneuralstemcellsinpatientswithamyotrophiclateralsclerosis:resultsofaphaseItrialin12patients.StemCells30(6),1144–1151.Riley,J.,Feldman,E.L.,2014.“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.Neurosurgery74(1),77–87RESULTS:Unilateralcervical(groupD,n=3)andcervicalplusthoracolumbar(groupE,n=3)microinjectionstotheventralhornhavebeencompletedinambulatorypatients.Onepatientdevelopedapostoperativekyphoticdeformitypromptingcompletionofalaminoplastyinsubsequentpatients.Anotherrequiredreoperationforwounddehiscenceandinfection.Thesolitarypatientwithbulbaramyotrophiclateralsclerosisrequiredperioperativereintubation.CONCLUSION:Deliveryofacellularpayloadtothecervicalorthoracolumbarspinalcordwaswelltoleratedbythespinalcordinthisvulnerablepopulation.Thisencouragingfindingsupportsconsiderationofthisdeliveryapproachforneurodegenerative,oncologic,andtraumaticspinalcordafflictions.IntraspinalstemcelltransplantationinALS:aphaseItrial,2014iPSCellsWereGeneratedfromPDpatientsandNormalControls6OHDAinducedRatPDModelHumaniPScellsIntegratedtotheHostBrainof6OHDAinducedRatPDModelHanF,WangW,ChenC,DuanJ,etalCytotherapy2015分化的胎腦神經(jīng)干細胞移植治療PD建立大鼠SCI損傷模型A.暴露和部分橫切脊髓外科手術。B.T7橫斷損傷產(chǎn)生后肢癱瘓。C.無脊髓損傷的正常大鼠。RTPCRtoDetecttheMicroRNAExpressioninRatSCIModelMiR-124MiR-124MiR-124MiR-127MiR-127MiR-127MiR-127MiR-124MiR-133aMiR-133aMiR-133aMiR-181aMiR-181aMiR-181aRealTimeRTPCRtoDetecttheMicroRNAExpressioninSCI干細胞移植修復脊髓神經(jīng)損傷移植神經(jīng)干細胞分化的神經(jīng)軸索與宿主脊髓神經(jīng)細胞及其樹突形成突觸連接LuPetal,Cell.2012September14;150(6):1264–1273BoneMarrowStromalCellIntraspinalTransplantsFailtoImproveMotorOutcomesinaSevereModelof

SCIJournalofNeurotrauma2015,TuszynskiMHTodeterminewhetherlocalmechanismsmediateBMSCneuroprotectiveactionsgraftedallogeneicBMSCstositesofsevere,compressive

spinalcordinjury

(SCI)inSpragueDawleyrats.

Cells

wereadministered48hoursaftertheoriginal

injury.AdditionalanimalsreceivedallogeneicMSCsthatweregeneticallymodifiedtosecreteBDNF,tofurtherdeterminewhetheralocallyadministeredneurotrophicfactorprovidesorextendsneuroprotection.twomonthspost-injury

inaclinicallyrelevantmodelofsevereSCI,BMSCgraftswithorwithoutBDNFsecretionfailedtoimprovemotoroutcomes.Thus,allogeneicgraftsofBMSCsdonotappeartoactthroughlocalmechanisms,andfuture

clinicaltrials

thatacutelydeliverBMSCstoactualsitesof

injury

withindaysareunlikelytobebeneficial.IntraspinalStemCellTransplantationinAmyotrophicLateralSclerosis:APhaseISafetyTrial,TechnicalNote,andLumbarSafetyOutcomesNEUROSURGERYVOLUME71|NUMBER2|AUGUST2012DepartmentofNeurosurgery,EmoryUniversity,Atlanta,Georgia;DepartmentofNeurology,EmoryUniversity,Atlanta,Georgia;DepartmentofNeurology,UniversityofMichigan,AnnArbor,Michigan神經(jīng)干細胞移植方法Eachmicroinjectionseriescomprised5injections(10mL/injection)separatedby4mm.Eachinjection:100000neuralstemcellsderivedfromafetalspinalcord.Twelvepatientsweretreatedwitheitherunilateralorbilateralinjections.Patientsarefollowedclinicallyandradiologicallytoassesspotentialtoxicityoftheprocedure.LumbarLaminectomyMicroinjectionplatformapplicationPostoperativeimagingprogressionRiley,J.,Feldman,E.L.,2014.“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.Neurosurgery74(1),77–87

ClinicalTrialsusingESCsandiPSCsThereisalsoareportofoneJapanesepatientwhoreceivedatransplantofasheetofiPSC-derivedRPESummaryonMolecularMechanismofStemCellTransplantationforNeurologicalDiseasesTransplantedcellssurvive,differentiatetoneurons,astrocytes,oligodendrocyteprecursors(hESC,hiPSC,NSC)andreleaseneurologicaltransmittorssuchasdopamine,Ach.Releaseofneurotrophicfactors(GDNF,GDNE,IGF,)toincreasethefunctionsoftheendogenousneuralstemcellsReleaseofimmuno-regulatoryfactorssuchasIL-2,6,8,10toplayimmuno-modulationandattenuationoftheinflammatoryprocess,suchasMSC.Thetransplantedcellsformedsynapsewithhostcells.OtherssuchasdelayingtheonsetandprolongingsurvivalofSOD1ratsIncreasinghostneurogenesisOleIsacsonetal,HarvardStemCellInstituteEachinjection:100000neuralstemcellsderivedfromafetalspinalcord.Cells

wereadministered48hoursaftertheoriginal

injury.sheetofiPSC-derivedRPEOtherssuchasdelayingtheonsetandprolongingsurvivalofSOD1ratsEachmicroinjectionseriescomprised5injections(10mL/injection)separatedby4mm.“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.SummaryonMolecularMechanismofStemCellTransplantationforNeurologicalDiseasesIntraspinalstemcelltransplantationinALS:aphaseItrial,2014Glass,Feldman,E.University,Atlanta,Georgia;DepartmentofNeurology,EmoryUniversity,Atlanta,Georgia;DepartmentofNeurology,UniversityofMichigan,AnnArbor,MichiganAmyotrophicLateralSclerosis:Cells

wereadministered48hoursaftertheoriginal

injury.ThereisalsoareportofoneJapanesepatientwhoreceivedatransplantofa,Feldman,E.AmyotrophicLateralSclerosis:2008May;14(5):504-6.“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.Twelvepatientsweretreatedwitheitherunilateralorbilateralinjections.Mendez,Isacsonetal,,NATUREMEDICINEVOLUME14(5):507-509,2008干細胞移植修復脊髓神經(jīng)損傷AmyotrophicLateralSclerosis:OleIsacsonetal,HarvardStemCellInstituteIntraspinalstemcelltransplantationinALS:aphaseItrial,2014“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.神經(jīng)退行性疾病干細胞移植治療目前研究現(xiàn)狀與未來展望Patientsarefollowedclinicallyandradiologicallytoassesspotentialtoxicityoftheprocedure.OleIsacsonetal,HarvardStemCellInstituteThisincludestheabsenceoftumorformationandGIDs(graft-induceddyskinesia)throughoutlong-termfollow-upperiods.2012September14;150(6):1264–1273Ubiquintin-GraftedNeuronsIncreasinghostneurogenesisEvaluationSystem(Symptoms,Dopaminerelease,Levodopa-response),UnifiedParkinson’sDiseaseRatingScale(UPDRS),BiomarkersTrial,TechnicalNote,andLumbarSafetyOutcomes“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.,Feldman,E.Adverseeffectsmustbeminimal.GraftednigralneuronswerefoundtohaveLewybody-likeinclusions14yearsaftertransplantationintothestriatumofanindividualwithPD“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.DopaminereleasefromtransplantedneuralstemcellsinParkinsonianratstriatuminvivo.分化的胎腦神經(jīng)干細胞移植治療PDiPSCellsWereGeneratedfromPDpatientsandNormalControlstoincreasethefunctionsoftheendogenousneuralstemcells6OHDAinducedRatPDModel2010Jan;51(1):7-15“IntraspinalstemcelltransplantationinALS:aphaseItrial,cervicalmicroinjectionandfinalsurgicalsafetyoutcomes”.ThereisalsoareportofoneJapanesepatientwhoreceivedatransplantofa-LongtermStudyThereisalsoareportofoneJapanesepatientwhoreceivedatransplantofaPatientsarefollowedclinicallyandradiologicallytoassesspotentialtoxicityoftheprocedure.Patientsarefollowedclinicallyandradiologicallytoassesspotentialtoxicityoftheprocedure.SCgraftsshouldexhibitregulatedreleaseofdopamineinlinewiththatofendogenousdopaminergicneurons.APhase

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論